GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Alexion Pharmaceuticals, Inc. (ALXN) [hlAlert]

Rating:
Overweight
ALXN
up 925.49 %

Alexion Pharmaceuticals, Inc. (ALXN) rated Overweight by Piper Jaffray

Posted on: Wednesday,  Nov 27, 2013  8:25 AM ET by Piper Jaffray

Piper Jaffray rated Overweight Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on 11/27/2013. Previously Piper Jaffray rated Buy Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) on
05/29/2008., when the stock price was $17.54. Since then, Alexion Pharmaceuticals, Inc. has gained 925.49% as of 12/11/2015's recent price of $179.82.
If you would have followed the previous Piper Jaffray's recommendation on ALXN, you would have gained 925.49% of your investment in 2752 days.

Alexion Pharmaceuticals develops pharmaceutical products for the treatment of heart disease, and inflammation, diseases of the immune system and cancer in humans. The company's lead product candidates are genetically altered antibodies that target specific diseases which arise when the human immune system induces undesired inflammation in the human body. These candidates are designed to block components of the human immune system which cause undesired inflammation while allowing beneficial components of the immune system to remain functional.

At Piper Jaffray, we understand there’s no substitute for relevant and timely research. That's why we provide: * fundamental and technical research * value-added investment ideas * market analysis With the information our research team provides, you’ll make better and more informed decisions for your portfolio.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
11/27/2013 8:25 AM Buy
None
123.10
as of 12/13/2013
1 Week down  -1.40 %
1 Month up  6.08 %
3 Months up  8.36 %
1 YTD up  31.95 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/12/2010 8:25 AM Buy
None
13.38
5/29/2008 8:25 AM Buy
None
17.54 22.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy